Results 31 to 40 of about 6,976 (207)

Toward a Practical, Two-Step Process for Molnupiravir from Cytidine [PDF]

, 2021
A two-step synthesis of molnupiravir (1) is presented. This work focuses on the development of practical reaction and purification conditions toward a manufacturing route.
Flavio S. P., Cardoso, Rodger W., Stringham, Natarajan, Vasudevan, Dinesh J., Paymode, Daniel W., Cook, Justina, Burns, Saeed, Ahmad, David, Snead, Appasaheb L., Kadam   +8 more
core   +2 more sources

New analytical method development and validation for estimation of molnupiravir in bulk and tablet dosage form by RP-HPLC method [PDF]

Cellular, Molecular and Biomedical Reports, 2023
A new simple, selective, rapid, precise reversed-phase high-performance liquid chromatography method has been developed and validated for the estimation of Molnupiravir in bulk and its pharmaceutical dosage form.
Gandu Sravanthi, Kumara Gandla, Lalitha Repudi   +2 more
doaj   +1 more source

Molnupiravir and Its Antiviral Activity Against COVID-19

Frontiers in Immunology, 2022
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) constitutes a major worldwide public health threat and economic burden.
Lili Tian, Zehan Pang, Maochen Li, Fuxing Lou, Xiaoping An, Shaozhou Zhu, Lihua Song, Yigang Tong, Huahao Fan, Junfen Fan   +9 more
doaj   +1 more source

Could chlorophyllins improve the safety profile of beta-d-N4-hydroxycytidine versus N-hydroxycytidine, the active ingredient of the SARS-CoV-2 antiviral molnupiravir?

Therapeutic Advances in Drug Safety, 2022
Plain Language Summary Could natural plant pigment (chlorophyll) derivatives (chlorophyllins) improve the safety of the antiviral Molnupiravir, used to treat COVID-19 disease?
Nicole F. Clark, Andrew W. Taylor-Robinson, Kirsten Heimann   +2 more
doaj   +1 more source

Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system

Frontiers in Pharmacology, 2023
Molnupiravir, an urgently approved drug during the Coronavirus Disease 2019 (COVID-19) pandemic, serves as the basis for our study, which relies on the Food and Drug Administration Adverse Event Reporting System (FAERS).
Yankun Liang, Yankun Liang, Lin Ma, Yuting Wang, Jingping Zheng, Ling Su, Jun Lyu, Jun Lyu   +7 more
doaj   +1 more source

Progress Towards a Large-Scale Synthesis of Molnupiravir (MK-4482, EIDD-2801) from Cytidine [PDF]

, 2021
Molnupiravir (MK-4482, EIDD-2801) is a promising orally bioavailable drug candidate for treatment of COVID-19. Herein we describe a supply-centered and chromatography-free synthesis of molnupiravir from cytidine, consisting of two steps: a
Catherine P., McGeough, Chris, Senanayake, Joseph D., Armstrong, Grace P., Ahlqvist, Tim, Jamison, Ajay, Yadaw, David R., Snead, Sarabindu, Roy, Saeed, Ahmad   +8 more
core   +2 more sources

Effectiveness of molnupiravir vs nirmatrelvir-ritonavir in non-hospitalised and hospitalised patients with COVID-19: a target trial emulation studyResearch in context

EClinicalMedicine, 2023
Summary: Background: Molnupiravir and nirmatrelvir-ritonavir have emerged as promising options for COVID-19 treatment, but direct comparisons of their effectiveness have been limited.
Eric Yuk Fai Wan, Vincent Ka Chun Yan, Zoey Cho Ting Wong, Celine Sze Ling Chui, Francisco Tsz Tsun Lai, Xue Li, Carlos King Ho Wong, Ivan Fan Ngai Hung, Chak Sing Lau, Ian Chi Kei Wong, Esther Wai Yin Chan   +10 more
doaj   +1 more source

Earth-friendly-assessed silver-nanoparticles spectrophotometric method for rapid and sensitive analysis of Molnupiravir, an FDA-approved candidate for COVID-19: application on pharmaceutical formulation and dissolution test

BMC Chemistry, 2023
Molnupiravir is the first oral direct-acting antiviral prodrug recently approved for the COVID-19 pandemic. Here and for the first time, we present a novel, sensitive, robust, and simple silver-nanoparticles spectrophotometric technique for molnupiravir ...
Ahmed R. Mohamed, Ebrahim Abolmagd, Israa M. Nour, Mohamed Badrawy, Mohamed A. Hasan   +4 more
doaj   +1 more source

Molnupiravir. Chinese

, 2021
Title from PDF caption (viewed on January 4, 2022)."OHA4029A12292021 SIMPLIFIED CHINESE"--Running footer.This archived document is maintained by the State Library of Oregon as part of the Oregon Documents Depository Program.

core   +1 more source

Comparison of the acceptability and safety of molnupiravir in COVID-19 patients aged over and under 80 years

Aging and Health Research, 2023
Background: Molnupiravir is being widely used as a treatment for coronavirus disease 2019 (COVID-19); however, its acceptability and safety in older patients aged ≥ 80 years in real-world clinical practice is not well understood.
Kohei Fujita, Osamu Kanai, Hiroaki Hata, Kenjiro Ishigami, Kazutaka Nanba, Naoki Esaka, Koichi Seta, Tadashi Mio, Takao Odagaki   +8 more
doaj   +1 more source